       Document 0134
 DOCN  M9620134
 TI    A decreasing CD4+/CD8+ ratio after one month of treatment with
       stanazolol in postmenopausal women.
 DT    9602
 AU    Zofkova I; Kancheva RL; Hampl R; Institute of Endocrinology, Prague,
       Czech Republic.
 SO    Steroids. 1995 Jul;60(7):430-3. Unique Identifier : AIDSLINE
       MED/96065927
 AB    Androgens influence some immunological processes, including the
       differentiation of T-cells in CD4+ (helpers) or CD8+
       (suppressors/cytotoxic) phenotype. In nine postmenopausal osteoporotic
       women the effect of stanazolol on lymphocyte counts, CD3+ and the
       immunoregulatory index (CD4+/CD8+) were investigated. In the placebo
       group, ten postmenopausal osteoporotic women of similar age were
       included. The means of the investigated indices after stanazolol as
       compared with the values before treatment were as follows: lymphocyte
       counts (cells/microL +/- SEM) 2974 +/- 225 versus 2313 +/- 166, CD3+ (%)
       54.3 +/- 5.5 versus 70.9 +/- 1.6 (P < 0.05); CD4+/CD8+ ratio 1.8 +/-
       0.02 versus 2.5 +/- 0.28 (P < 0.05). The values after placebo as
       compared with the values before placebo were: 2558 +/- 201 versus 2370
       +/- 256, 62.9 +/- 2.1 versus 64.8 +/- 1.7 and 1.6 +/- 0.2 versus 1.6 +/-
       0.1 in sequence. The treatment was controlled by the serum stanazolol
       levels before and after steroid administration (unmeasurable versus 20.8
       +/- 3.4 nmol/L, P < 0.01). The good compliance of the therapy was
       confirmed by a decline of serum LH (U/L; 30.1 +/- 3.1 versus 24.7 +/-
       2.8, P = 0.014), FSH (U/L; 108.9 +/- 13.1 versus 93.3 +/- 12.8, P =
       0.012) and serum sex hormone binding globulin (SHBG; nmol/L; 53.3 +/-
       13.3 versus 11.2 +/- 1.9, P < 0.01). The decline of SHBG indicates a
       good tissue sensitivity to the androgen. There were no significant
       differences between hormonal parameters before and after placebo
       treatment. In conclusion, the immunosuppressive effect of the androgen,
       stanazolol, was confirmed in the investigated postmenopausal
       osteoporotic women.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Anabolic Steroids/*THERAPEUTIC USE  *CD4-CD8 Ratio  Female  FSH/BLOOD
       Human  LH/BLOOD  Middle Age  Osteoporosis, Postmenopausal/*DRUG
       THERAPY/*IMMUNOLOGY  Placebos  Sex Hormone-Binding Globulin/METABOLISM
       Stanozolol/BLOOD/*THERAPEUTIC USE  Support, Non-U.S. Gov't  CLINICAL
       TRIAL  CONTROLLED CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

